Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798405 · ClinicalTrials.gov registry record · NA
Reactive vs. Proactive Pain Control in IBD
A NA study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT03798405 is a NA study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT03798405, a NA study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The investigators will compare two physician behaviors for managing pain in patients with IBD: proactive vs. reactive. Both the proactive and reactive behavior/strategies are standard of care at the institution in which the study will be performed. The PROACTIVE strategy is an IBD-specific analgesic orderset (built into our EMR and approved by the institution's Pharmacy and Therapeutics committee), the REACTIVE strategy is a traditional "reactive" analgesic prescribing (prescribing medications only when patients have pain). The PROACTIVE IBD-specific analgesic orderset consists of medications which have evidence for use in IBD-related pain. This orderset is an educational guide, it does not force any order. The reactive prescribing habits could contain an array of pain medications depending on what the provider wants to prescribe. Aims: Aim 1: To assess whether there is a difference in pain scores or functional activity among hospitalized patients with IBD between reactive vs proactive physician behaviors. Aim 2: To assess whether there is a difference in inpatient opioid-prescribing between reactive vs proactive physician behaviors. Aim 3: To assess whether there is a difference in health care utilization, including length-of-stay and 30-day readmission, between reactive vs proactive physician behaviors.
Interventions
- BEHAVIORAL Proactive Analgesic Inpatient Narcotic-Sparing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2022-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798405
The ClinicalTrials.gov registry entry for NCT03798405 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Proactive Analgesic Inpatient Narcotic-Sparing is the first listed.
NCT03798405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03798405 about?
NCT03798405 is a clinical study titled "Reactive vs. Proactive Pain Control in IBD". The investigators will compare two physician behaviors for managing pain in patients with IBD: proactive vs. reactive. Both the proactive and reactive behavior/strategies are standard of care at the institution in which the study will be performed. The PROACTIVE strategy is an IBD-specific analgesic...
What is the current status of trial NCT03798405?
This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2019-01-01. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT03798405?
The interventions under investigation include: Proactive Analgesic Inpatient Narcotic-Sparing (BEHAVIORAL).
Who is sponsoring clinical trial NCT03798405?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.